

## DAFTAR PUSTAKA

1. Elder DE, Elenitsas R, Rosenbach M, Murphy GF, Rubin AI, Xu X, editors. *WHO Classification of Skin Tumours*. 5th ed. Lyon: International Agency for Research on Cancer (IARC); 2018.
2. Davids LM. Recent Advances in the Biology, Therapy and Management of Melanoma. Croatia: InTech; 2013. doi:10.5772/46052
3. Akdeniz M, Hahnel E, Ulrich C, Blume-Peytavi U, Kottner J. Prevalence and associated factors of skin cancer in aged nursing home residents: A multicenter prevalence study. *PLoS One*. 2019 Apr 1;14(4). doi:10.1371/journal.pone.0215379 PubMed PMID: 31009466.
4. Xu J, Wang X, Liu W, Liu X, Li G. Analysis and comparison of the trends in burden of malignant cutaneous melanoma in East Asian countries and regions and worldwide from 1991 to 2021. *Front Public Health*. 2025 Apr 30;13. doi:10.3389/fpubh.2025.1487177
5. Huang J, Chan SC, Ko S, Lok V, Zhang L, Lin X, et al. Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries. *Am J Clin Dermatol*. 2023 Nov 10;24(6):965–75. doi:10.1007/s40257-023-00795-3
6. Aries A, Fathin M. Karakteristik Penderita Melanoma Malignant di Rumah Sakit Umum Pusat Dr. Wahidin Sudirohusodo Tahun 2022-2024. [Skripsi]. Makasar: Fakultas Kedokteran Universitas Hasanuddin; 2024.
7. Paramartha GNAA, Niryana IW, Adiputra PAT. Karakteristik Pasien Melanoma Maligna di Subbagian Bedah Onkologi RSUP Sanglah Tahun 2015-2016. *Intisari Sains Medis*. 2019 Jun 17;10(2). doi:10.15562/ism.v10i2.242
8. Strashilov S, Yordanov A. Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances. *International Journal of Molecular Sciences*. 2021;22(12):6395. doi:10.3390/ijms22126395
9. Zhou L, Zhong Y, Han L, Xie Y, Wan M. Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990–2021 *Scientific Reports*. 2025;15:5996. doi:10.1038/s41598-025-90485-3
10. Ricci F, Pistore G, Di Lella G, Fania L, Ricci F, Rahimi S, et al. Getting even: occurrence of histopathological primitive melanoma diagnoses three years after



- the COVID-19 lockdown. *Dermatology Reports*. 2025 Jul 23. doi:10.4081/dr.2025.10318
11. Bastian A, Nichita L, Zurac S. Matrix Metalloproteinases in Melanoma with and without Regression. In: *The Role of Matrix Metalloproteinase in Human Body Pathologies*. InTech; 2017. doi:10.5772/intechopen.72931
  12. Tas F. Metastatic behavior in melanoma: Timing, pattern, survival, and influencing factors. *Journal of Oncology*. 2012. doi:10.1155/2012/647684 PubMed PMID: 22792102.
  13. Thompson JF, Williams GJ. When does a melanoma metastasize? Implications for management. *Oncotarget* [Internet]. 2024. Available from: [www.oncotarget.com](http://www.oncotarget.com)
  14. Singvogel K, Schitteck B. Dormancy of cutaneous melanoma. *Cancer Cell International*. 2024;24:88. doi:10.1186/s12935-024-03278-5
  15. Mandalà M, Massi D. Tissue prognostic biomarkers in primary cutaneous melanoma. *Virchows Archiv. Springer Verlag*; 2014;464:265–281. doi:10.1007/s00428-013-1526-x PubMed PMID: 24487785.
  16. Zablocka T, Kreismane M, Pjanova D, Isajevs S. Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. *Oncology Letters*. 2023;25(1). doi:10.3892/ol.2022.13613
  17. James W Patterson. *Weedon's Skin Pathology*. 5th ed. Greenville: Elsevier; 2016.
  18. Vița O, Jurescu A, Văduva A, Cornea R, Cornianu M, Tăban S, et al. Invasive Cutaneous Melanoma: Evaluating the Prognostic Significance of Some Parameters Associated with Lymph Node Metastases. *Medicina (Lithuania)*. 2023;59(7). doi:10.3390/medicina59071241 PubMed PMID: 37512052.
  19. Vineis P. Melanoma thickness and long-term mortality. *Journal of the National Cancer Institute*. Oxford University Press; 2025. p. 1–2. doi:10.1093/jnci/djae236 PubMed PMID: 39401264.
  20. Barricklow Z, Di Vincenzo MJ, Angell CD, Carson WE. Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype. *Clinical, Cosmetic and Investigational Dermatology*. Dove Medical Press Ltd; 2022. p. 1743–57. doi:10.2147/CCID.S372287

21. Yuvruk M, Girgin RB, Zemheri E. Evaluation of MMP-9, MMP-13, MMP-21, and TIMP-1 expressions in malign melanom, dysplastic nevi, and banal nevi. *North Clin Istanbul*. 2024;11(2):158–66. doi:10.14744/NCI.2023.69009
22. Nikkola J, Kellokumpu-Lehtinen P, Ka ha ri VM, Pyrho nen S. High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1Are Associated with Rapid Progression in Patients with Metastatic Melanoma. *Clinical Cancer Research*. 2005; 11 (14): 5158–5166
23. Austin M, Minghao Z, John S. Clinical, Pathologic, and Molecular Features of BAP-1 Mutated Uveal Melanoma . In: *Laboratory Investigation The Basic and Translational Pathology Research Journal*. Springer Nature; 2021.
24. Zhou Y, Nelson AC, He Y, Munro SA, Song KY, Domingo-Musibay E, et al. Gene expression and mutational profile in *bap-1* inactivated melanocytic lesions of progressive malignancy from a patient with multiple lesions. *Genes (Basel)*. 2022 Jan 1;13(1). doi:10.3390/genes13010010 PubMed PMID: 35052351.
25. Leonardi G, Falzone L, Salemi R, et al. Cutaneous melanoma: From pathogenesis to therapy (Review). *International Journal of Oncology*. 2018; 52(4):1071-1080. doi:10.3892/ijo.2018.4287
26. Elder DE, Elenitsas R, Rosenbach M, Murphy GF, Rubin AI, Xu X, editors. *Lever’s Histopathology of the Skin*. philadelphia: wolters kluwer; 2001.
27. Thompson JF, Morton DL, Kroon B, editors. *Textbook of Melanoma*. CRC Press; 2003.
28. Sundararajan S, Thida AM, Yadlapati S. *Metastatic Melanoma*. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2025.
29. Lazar AM, Costea DO, Popp CG, Mastalier B. Skin Malignant Melanoma and Matrix Metalloproteinases: Promising Links to Efficient Therapies. *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute (MDPI); 2024; Jul 17;25(14):7804. doi:10.3390/ijms25147804 PubMed PMID: 39063046.
30. Manolescu BSM, Lazar AM, Țiplica GS, Zurac SA, Reboșapcă A, Andreescu B, et al. MMP1, MMP9, MMP11 and MMP13 in melanoma and its metastasis – key points in understanding the mechanisms and celerity of tumor dissemination.

- Romanian Journal of Morphology and Embryology. 2024; Jan 1;65(1):45–52. doi:10.47162/RJME.65.1.06 PubMed PMID: 38527983.
31. Garutti M, Bruno R, Polesel J, Pizzichetta MA, Puglisi F. Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis. *Heliyon*. 2024; Jun 30;10(12). doi:10.1016/j.heliyon.2024.e32433
  32. Rossi S, Cordella M, Tabolacci C, Nassa G, D’Arcangelo D, Senatore C, et al. TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness. *Journal of Experimental and Clinical Cancer Research*. 2018; Dec 28;37(1). doi:10.1186/s13046-018-0982-1 PubMed PMID: 30591049.
  33. Yousefi NK, Muhammadnejad A, Rahmati M, Ghanadan A, Razavirad A. document. *Asian Pacific Journal of Cancer Biology*. 2024;9(3). doi:DOI:10.31557/APJCB.2024.9.3.329
  34. Gui J, Guo Z, Wu D. Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma. *Journal of Translational Medicine*. BioMed Central Ltd; 2022. doi:10.1186/s12967-022-03532-2 PubMed PMID: 35974375.
  35. Yuvruk M, Girgin RB, Zemheri E. Evaluation of MMP-9, MMP-13, MMP-21, and TIMP-1 expressions in malign melanom, dysplastic nevi, and banal nevi. *North Clin Istanb*. 2024;11(2):158–66. doi:10.14744/NCI.2023.69009
  36. Chang M. Matrix metalloproteinase profiling and their roles in disease. *RSC Advance*. 2023;13(9):6304–16. doi:10.1039/D2RA07005G
  37. Toby Thomas J, Joseph B, Waltimo T, Anil S. Matrix Metalloproteinases (MMPs) in Periodontium: Is It a Boon or a Bane? In. 2024. doi:10.5772/intechopen.114353
  38. Napoli S, Scuderi C, Gattuso G, Di Bella V, Candido S, Basile MS, et al. Functional roles of matrix metalloproteinases and their inhibitors in melanoma. *Cells*. Multidisciplinary Digital Publishing Institute (MDPI). 2020;9(5):1151. doi:10.3390/cells9051151 PubMed PMID: 32392801.
  39. Augoff K, Hryniewicz-Jankowska A, Tabola R, Stach K. MMP9: A Tough Target for Targeted Therapy for Cancer. *Cancers*. Multidisciplinary Digital Publishing Institute (MDPI). 2022; 14(7), 1847. doi:10.3390/cancers14071847

40. Heikenwalder M, Lorentzen A. The role of polarisation of circulating tumour cells in cancer metastasis. *Cellular and Molecular Life Sciences*. 2019 Oct 19;76(19):3765–81. doi:10.1007/s00018-019-03169-3
41. Kaisman-Elbaz T, Haddad-Shlaifshtein S, Eskira Y, Merkin V, Dumanis G, Turiel S, et al. High intra-tumoral and serum matrix metalloproteinase 9 levels are associated with reduced survival of patients with glioblastoma and brain metastases. *Frontiers in Oncology*. 2026; 15:1577492. doi:10.3389/fonc.2025.1577492
42. Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, et al. MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA. *Front Pharmacol*. 2018;9:856. doi:10.3389/fphar.2018.00856
43. Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, et al. Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma. *BMC Med Genet*. 2007;8:10. doi:10.1186/1471-2350-8-10 PubMed PMID: 17346338.
44. Khambri D, Suyuthie HD, Hilbertina N, Yetti H, Purwanto DJ. Matrix Metalloproteinase-9 as Prognostic Factor for the Treatment of HER-2 Enriched Breast Cancer. *Asian Pacific Journal of Cancer Prevention*. 2022;23(3):1013–1021. doi:10.31557/APJCP.2022.23.3.1013 PubMed PMID: 35345375.
45. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. *Hum Pathol*. 2008;39(3):377–385. doi:10.1016/j.humpath.2007.06.021 PubMed PMID: 18187184.
46. Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. *PLOS One*. 2012;7(3):e32955. doi:10.1371/journal.pone.0032955 PubMed PMID: 22412958.
47. LeBlanc RE. *Pathology Outline*. 2023. skin tumor melanocytic melanoma staging.
48. Scolyer RA, Judge MJ, Evans A, Frishberg DP, Prieto VG, Thompson JF, et al. Data Set for Pathology Reporting of Cutaneous Invasive Melanoma Recommendations From the International Collaboration on Cancer Reporting (ICCR) [Internet]. 2013. Available from: [www.ajsp.com](http://www.ajsp.com)

49. Guarneri C, Bevelacqua V, Polesel J, Falzone L, Cannavo PS, Spandidos DA, et al. NF- $\kappa$ B inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma. *Oncol Rep.* 2017;37:737–746. doi:10.3892/or.2017.5362 PubMed PMID: 28075446.
50. Chen J, Xu Y, Zhou Y, Wang Y, Zhu H, Shi Y. *Oncotarget* 45671 www.impactjournals.com/oncotarget Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data. *Oncotarget* [Internet]. 2016. Available from: www.impactjournals.com/oncotarget/
51. Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. *BMC Cancer.* 2014 Aug 23;14(1). doi:10.1186/1471-2407-14-609 PubMed PMID: 25151367.
52. Ward WH, Farma JM. CUTANEOUS MELANOMA Etiology and Therapy. 2017. doi:DOI: http://dx.doi.org/10.15586/codon.cutaneousmelanoma.2017
53. Altan Ferhatoglu Z, Tas F. Avoiding Cutaneous Melanoma Requires Proper Sun Protection and a Correspondingly High Level of Education: A Case Control Study. *J Cosmet Dermatol.* 2025 Feb 10;24(2). doi:10.1111/jocd.16677
54. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer Journal of Clinicians.* 2018 Nov;68(6):394–424. doi:10.3322/caac.21492 PubMed PMID: 30207593.
55. Du R, Guo J, Li J, Lyu J. Age-period-cohort Analysis of Cutaneous Malignant Melanoma Incidence in the United States from 1987 to 2016. *Cancer Screening and Prevention.* 2024 Sep 25;3(3):133–41. doi:10.14218/CSP.2024.00019
56. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long G V., Ross MI, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer Journal of Clinicians.* 2017 Nov 13;67(6):472–92. doi:10.3322/caac.21409
57. Puckett Y, Wilson AM, Farci F. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/sites/books/NBK459367/>. Melanoma Pathology. [Updated 2024 Jul 2].

58. Marcos N, Júnior F, Muller H, Ribeiro M, Maia M, Antonio J, et al. Cutaneous melanoma: descriptive epidemiological study. *Sao Paulo Medical Journal*. 2008 Jan 2;126(1):41-7. doi: 10.1590/s1516-31802008000100008.
59. Xavier MHSB, Drummond-Lage AP, Baeta C, Rocha L, Almeida AM, Wainstein AJA. Delay in cutaneous melanoma diagnosis. *Medicine*. 2016 Aug;95(31):e4396. doi:10.1097/MD.0000000000004396
60. Redondo P, Lloret P, Idoate M, Inogest S. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. *Clinical and Experimental Dermatology*. 2005;30:541–545. doi:10.1111/j.1365-2230.2005.01849.x PubMed PMID: 16045689.
61. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nature Reviews Cancer*. 2002;2:161–174. doi:10.1038/nrc745
62. Kumar V, Abbas AK, Aster JC, Debnath J, Das A. Robbins and Cotran Pathologic Basis of Disease. 11th ed. Elsevier Health Sciences; 2025.
63. Pop AM, Monea M, Olah P, Moraru R, Cotoi OS. The Importance of Immunohistochemistry in the Evaluation of Tumor Depth of Primary Cutaneous Melanoma. *Diagnostics*. 2023 Mar 1;13(6). doi:10.3390/diagnostics13061020
64. Barricklow Z, Di Vincenzo MJ, Angell CD, Carson WE. Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype. *Clinical, Cosmetic and Investigational Dermatology*. Dove Medical Press Ltd; 2022. p. 1743–57. doi:10.2147/CCID.S372287
65. Chen Y, Chen Y, Huang L, Yu J. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. *Journal of Dermatology*. 2012 Apr;39(4):339–43. doi:10.1111/j.1346-8138.2011.01441.x PubMed PMID: 22150440.
66. Jewell R, Elliott F, Laye J, Nsengimana J, Davies J, Walker C, et al. The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. *Pigment Cell Melanoma Res*. 2015 Jan 1;28(1):94–104. doi:10.1111/pcmr.12315 PubMed PMID: 25220403.
67. Hout FEM, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, Scolyer RA. Prognostic Importance of the Extent of Ulceration in Patients With Clinically

- Localized Cutaneous Melanoma. *Annals of Surgery*. 2012;255:1165–1170. doi:10.1097/SLA.0b013e31824c4b0b
68. Barillari G. The impact of matrix metalloproteinase-9 on the sequential steps of the metastatic process. *International Journal of Molecular Sciences*. MDPI AG; 2020. p. 1–29. doi:10.3390/ijms21124526 PubMed PMID: 32630531.
69. Kondratiev S, Gnepp DR, Yakirevich E, Sabo E, Annino DJ, Rebeiz E, et al. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. *Hum Pathol*. 2008 Mar;39(3):337–43. doi:10.1016/j.humpath.2007.07.003

